Search
Search Results
##search.searchResults.foundPlural##
-
IMMUNOTHERAPY FOR EPSTEIN-BARR VIRUS-RELATED LYMPHOMAS
1138PDF: 592HTML: 6788 -
MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
2243PDF: 1309HTML: 17066Bassan Fig.1: 135Bassan Fig.2: 137Bassan Fig.4: 129Fig.3: 172 -
Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA
1496PDF: 1168HTML: 173 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1462PDF: 909HTML: 213 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2025PDF: 1624HTML: 349 -
HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS
1968PDF: 741HTML: 3104 -
CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA CAR T Cells and Myeloma Treatment
1668PDF: 815HTML: 138 -
CMV IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
4735PDF: 1730HTML: 2691Untitled: 197 -
Focusing On A Unique Innate Memory Cell Population Of Natural Killer Cells In The Fight Against COVID-19: Harnessing The Ubiquity Of Cytomegalovirus Exposure Memory Cell Population Of Natural Killer Cells in COVID-19 and Cytomegalovirus Exposure
1111PDF: 888HTML: 282 -
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment
2019PDF: 1482HTML: 264 -
THE ROLE OF SLC22A4 IN ACUTE MYELOID LEUKEMIA
441PDF: 228HTML: 75 -
TOLL-LIKE RECEPTORS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2533PDF: 848HTML: 17455Fig1 Caligaris: 153Fig.2 Caliga: 184 -
REGULATORY T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2277PDF: 951HTML: 7607Untitled: 259Fig2: 169Fig3: 152Fig4: 167 -
Is laboratory monitoring useful in DOACs management?
802PDF: 782HTML: 100 -
BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA BLINATUMOMAB and ALL
1564PDF: 1056HTML: 104 -
CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES CAR-T CELL FOR T-CELL MALIGNANCIES
2121PDF: 1960HTML: 158 -
NOVEL DRUGS IN FOLLICULAR LYMPHOMA
4265PDF: 1460HTML: 1535Untitled: 212 -
APLASTIC ANEMIA AND VIRAL HEPATITIS
1227PDF: 517HTML: 23014 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
1999PDF: 1407HTML: 252 -
CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CAR-T CELL and B-ALL
3882PDF: 3190HTML: 188 -
THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.
4002PDF: 1122HTML: 1922Fig.1: 209Fig. 2: 104Table 1: 190Table2: 204Table 3: 185 -
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
4245PDF: 1710HTML: 1098 -
REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY Real-world Assessment of Myeloma Patients as Candidates for CAR-T Therapy
1515PDF: 575HTML: 175 -
CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS CAR-T and Follicular Lymphoma
2189PDF: 1766HTML: 132 -
ROLE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION
1983PDF: 776HTML: 1028 -
OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANT BEFORE AVAILABILITY OF CAR-T CELL TREATMENT Outcome of DLBCL patients relapsing after ASCT
1252HTML: 288PDF: 910Suppl. Files: 436 -
PLASMACELL NEOPLASMS WITH SPREADING IN THE BLOOD AND TISSUES: EXTRAMEDULLARY MYELOMA DISEASE A RARE AGGRESSIVE FORM OF MULTIPLE MYELOMA (First of two parts) Extra Medullary Myeloma
2399HTML: 257PDF: 841 -
COVID-19 IN CHILDREN AND ADOLESCENT: CHARACTERISTICS AND SPECIFICITIES IN IMMUNOCOMPETENT AND ONCOHEMATOLOGICAL PATIENTS COVID-19 IN CHILDREN AND ADOLESCENT.
2173PDF: 917HTML: 286 -
IMMUNOLOGICAL DEREGULATION IN HODGKIN’S DISEASE
2183PDF: 937HTML: 1878 -
CLINICAL ASPECTS AND THERAPY OF SPORADIC BURKITT LYMPHOMA
1246PDF: 595HTML: 3063 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2761PDF: 988HTML: 5505







